Amoéba Enters New Phase with Biocontrol Solution Commercialization
Lyon, April 9, 2026 – Amoéba, a Lyon-based greentech company, has delivered the first order of its biocontrol product designed to protect vines and vegetable crops. Further commercial developments are underway for the cereal market. This marks a new chapter for the company, which has seen rapid acceleration in recent months.
Regulatory Approvals Pave the Way for Axpera
Amoéba, which develops natural microbiological solutions based on the patented use of an amoeba, obtained marketing authorization for its biocontrol solution, Axpera, in the American market in October 2025. Jean-François Doucet, CEO of Amoéba, stated, “Our active substance was approved in mid-2025 at the European level, and we are currently undergoing approval by ANSES for our product.”
The agricultural sector’s anticipation for such solutions is high. As in 2025, agricultural and wine-growing industries have filed for a derogation marketing authorization. “Since 2008, 50% of chemical active substances have been withdrawn from the market. Farmers and winegrowers are in a technical deadlock, and there is an urgent need for an effective innovation,” emphasized Doucet. Amoéba has already demonstrated its effectiveness, particularly in combating downy mildew. “For organic winegrowers, copper is the only weapon against downy mildew,” he added.
Strategic Partnerships and Market Expansion
While a final regulatory step still needs to be taken in Europe, the Chassieu-based company has already moved into a new phase of development. Following a distribution agreement signed in June 2025 with Koppert, a global leader in biocontrol, the initial deliveries are now in progress. This order will meet the demands of winegrowers in France, Italy, and the Netherlands before more broadly targeting the vine and vegetable crop markets in Europe and the United States.
“Our agreement also provides for the co-development of new solutions, for example, for soybean cultivation in Brazil,” the director noted. He hopes to finalize another agreement with the Syngenta group by the end of spring to target the cereal market, starting with wheat, and to also carry out co-developments with this partner.
Advancements in the Cosmetics Sector
“We chose to prioritize commercial activity and not invest millions of euros in a production tool, even though we have a small unit in Chassieu,” continued Jean-François Doucet. Amoéba is therefore working with two subcontractors to industrialize production, aiming for up to 30,000 liters per bioreactor. In parallel, the SME of 27 people is also exploring the cosmetics market.
“In vitro and clinical studies have highlighted the effectiveness of our ingredient for skin care, particularly concerning suppleness and radiance,” the director reported. Last summer, Amoéba signed an agreement with Metron Technology, a subsidiary of the Chinese group Oriental Beauty Valley, with a view to obtaining approval, expected at the start of the academic year, and then distribution of its ingredient in China in the first half of 2027.
The success of the capital increase, with 6.67 million euros raised, and a new debt repayment schedule provide Amoéba with room for maneuver in the coming months.
Industry Context and Future Outlook
The company’s strategic moves come at a time when the demand for sustainable agricultural solutions is growing. The reduction of chemical active substances in the market has created a significant gap that companies like Amoéba are aiming to fill with innovative and environmentally friendly alternatives. The dual focus on agriculture and cosmetics demonstrates Amoéba’s commitment to diversifying its applications and maximizing the potential of its patented amoeba technology.
The expansion into the cereal market with Syngenta and the entry into the Chinese cosmetic market through Metron Technology are crucial steps for Amoéba’s global growth. These partnerships not only provide access to new markets but also facilitate further research and development, ensuring the continuous evolution of their product offerings.
Amoéba’s journey from regulatory approvals to commercialization underscores a broader trend in the greentech sector, where scientific innovation is increasingly translating into tangible market solutions. The company’s ability to secure significant funding and forge strategic alliances positions it as a key player in the evolving landscape of biocontrol and sustainable technology.
Source: https://www.affiches-parisiennes.com/69680-chassieu/amoeba-ouvre-une-nouvelle-page-avec-la-commercialisation-de-sa-solution-de-biocontrole-244045.html
